PUBLISHER: The Business Research Company | PRODUCT CODE: 1751151
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751151
Urinary retention therapeutics encompass a range of medical treatments designed to address the inability to fully empty the bladder. These therapies aim to relieve bladder pressure, restore normal urinary flow, and prevent complications such as infections or kidney damage. The primary objective is to improve bladder function and enhance the patient's comfort and overall quality of life.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main urinary retention therapeutics include 5-alpha-reductase inhibitors and alpha-blocker drugs, anticholinergic or antispasmodic agents, antidepressants, skeletal muscle relaxants, topical estrogens, and others. 5-alpha-reductase inhibitors and alpha-blocker drugs are commonly used to treat benign prostatic hyperplasia (BPH). The former works by reducing prostate size through blocking the hormone dihydrotestosterone (DHT), while the latter helps relax muscle fibers in the prostate and bladder neck to improve urine flow. These treatments are used for conditions such as stress incontinence, urge incontinence, overflow incontinence, mixed incontinence, and others. They are administered through various routes, including oral, intravesical, intravenous, and transdermal, and are distributed through channels such as retail pharmacies, hospital pharmacies, and online pharmacies.
The urinary retention therapeutics market research report is one of a series of new reports from The Business Research Company that provides urinary retention therapeutics market statistics, including urinary retention therapeutics industry global market size, regional shares, competitors with a urinary retention therapeutics market share, detailed urinary retention therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the urinary retention therapeutics industry. This urinary retention therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The urinary retention therapeutics market size has grown strongly in recent years. It will grow from$3.33 billion in 2024 to $3.58 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historical period can be attributed to the rising incidence of urological disorders, increased healthcare spending, a growing global geriatric population, a higher prevalence of urinary incontinence (UI), and an escalating risk of related urological conditions among individuals.
The urinary retention therapeutics market size is expected to see strong growth in the next few years. It will grow to$4.75 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The projected growth during the forecast period can be attributed to the increasing demand for home-based care, a rising number of prostate cancer cases, growing demand for minimally invasive procedures, an increase in research initiatives, and a larger geriatric population. Key trends expected in the forecast period include the development of new and innovative treatment options, the advancement of urinary incontinence devices, technological innovations, strategic partnerships and collaborations, the rise of invasive OTC devices, and the growth of wearable technologies.
The growing incidence of prostate cancer is expected to drive the expansion of the urinary retention therapeutics market during the forecast period. Prostate cancer is a malignant condition characterized by uncontrolled cell growth in the prostate gland. The rise in prostate cancer cases is primarily due to demographic changes, with more men living longer lives. As the population ages, the risk of developing age-related diseases, including prostate cancer, naturally increases. Urinary retention therapeutics are vital for prostate cancer patients because the tumor or an enlarged prostate can block the urethra, making urination difficult and requiring treatments to restore normal urine flow. For example, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that 33,363 men in the United States died from prostate cancer in 2022, while 236,659 new cases were diagnosed in 2021. Consequently, the growing number of prostate cancer cases will drive the demand for urinary retention therapeutics.
Key companies in the urinary retention therapeutics market are focusing on advanced technologies, such as next-generation sacral nerve stimulation therapy, to improve bladder and bowel control. Sacral nerve stimulation therapy uses mild electrical impulses to stimulate the sacral nerves, helping relieve symptoms of urinary retention or overactive bladder. For instance, in February 2022, Medtronic Plc, an Ireland-based medical device company, received approval from the U.S. Food and Drug Administration (FDA) for its InterStim X system, marking a significant advancement in personalized sacral nerve stimulation therapy. The InterStim X system features a long-lasting, recharge-free battery, MRI compatibility, and a smart programmer for tailored therapy. Its two-stage implantation process allows for a trial period before permanent placement. These innovations enhance the convenience and safety of managing bladder and bowel control. The InterStim systems offer two long-term options: the recharge-free InterStim X and the rechargeable InterStim Micro, both designed for conditions such as overactive bladder and chronic fecal incontinence.
In September 2023, Caldera Medical, a U.S.-based medical device company specializing in women's health, acquired Atlantic Therapeutics for an undisclosed amount. This acquisition allows Caldera Medical to expand its women's health portfolio by integrating the FDA-cleared Innova product family, which provides non-invasive treatments for stress urinary incontinence (SUI). Atlantic Therapeutics, an Ireland-based medical technology company, focuses on bladder control treatments, aligning with the urinary retention therapeutics market.
Major players in the urinary retention therapeutics market are Pfizer Inc., Merck KGaA, Abbvie Inc., Bayer AG, Sanofi SA, GlaxoSmithKline Plc., Medtronic Plc, Eli Lilly and Company, Boston Scientific Corp., Sumitomo Pharma Inc., Ipsen Pharma, Coloplast A/S, Dr. Reddy's Laboratories, Cipla Limited, Amneal Pharmaceuticals Inc., Ferring Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., NYMOX CORPORATION, Antev Ltd., Amber Therapeutics, Implantica Patent Ltd.
North America was the largest region in the urinary retention therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in urinary retention therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the urinary retention therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The urinary retention therapeutics market consists of revenues earned by entities by providing services such as drug development and formulation services, clinical trial management, regulatory consulting and medical device integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary retention therapeutics market also includes sales of catheters, prostate shrinking agents, urethral stents and sacral neuromodulation devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Urinary Retention Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on urinary retention therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for urinary retention therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinary retention therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.